Decreased levels of EHHADH gene expression often correlate with a poorer prognosis for HCC patients (Figure 10J–10O), and targeting the activation of EHHADH may represent a viable strategy to prolong patients’ survival. This evidence concerns the gene EHHADH and hepatocellular carcinoma.